Key Stats for Eli Lilly Stock
- Price change for Eli Lilly stock in last 6 months: 27%
- $LLY Stock Price as of Sep. 21: $1,165
- 52-Week High: $1,292
- $LLY Stock Price Target: $1,325
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Eli Lilly (LLY) stock is drawing fresh attention today after Guggenheim raised its price target to $1,284 from $1,273 and maintained a Buy rating.
Eli Lilly currently has a market cap of $1.03 trillion. Guggenheim updated its model based on prescription trends, average selling price estimates, currency adjustments, and the news that Zepbound will return to CVS’s formulary starting October 1.
The firm sees the U.S. tirzepatide business, which includes both Mounjaro and Zepbound, staying strong.
Guggenheim’s prescription-based forecasts for 2027 and 2028 point to continued growth for both drugs, even though the firm expects mid- to high-single-digit price declines each year through the end of 2028.
Guggenheim also raised its outlook for Foundayo, Lilly’s oral drug.
Although the firm lowered its price assumption for the 2.5mg dose for the rest of this year, it raised its 2027 estimate to $1.8 billion from $1.2 billion and its 2028 estimate to $3.7 billion from $2.4 billion. That increase reflects an improving launch trajectory for the drug.
Guggenheim’s 2026 revenue estimate of $89.2 billion sits above Lilly’s guidance range of $85 billion to $87 billion and above the Street’s estimate of $88.3 billion.
The firm says it’s looking forward to learning more at the upcoming EASD meeting about the broader potential of retatrutide and eloralintide, especially when combined with tirzepatide.
Other analysts have echoed this bullish tone recently.
Berenberg upgraded Eli Lilly stock from Hold to Buy and raised its price target to $1,400, citing strong returns on investment and growth in the obesity treatment market.
BMO Capital reiterated its Outperform rating with a $1,400 price target, expecting Foundayo’s approval in type 2 diabetes to add further revenue growth.
Foundayo has already brought in roughly $100 million in sales during Q2 of 2026.
Separately, Lilly also announced a partnership with Twist Bioscience to strengthen its AI and machine learning drug discovery platform, TuneLab, with Twist providing antibody characterization data services to help speed up development.
See analysts’ growth forecasts and price targets for Eli Lilly stock (It’s free) >>>
What the Market Is Telling Us About Eli Lilly Stock
The wave of price target increases and analyst upgrades shows growing confidence that Eli Lilly stock’s weight-loss and diabetes portfolio still has plenty of room to run.
According to InvestingPro analysis, the stock appears undervalued at current levels, even after its strong 50% revenue growth.
With multiple firms now pointing to Foundayo’s improving launch trends and steady demand for Mounjaro and Zepbound, the market seems to be betting that Eli Lilly stock’s growth story in metabolic health is far from finished.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Eli Lilly Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
